The Swiss pharma is paying $60 million upfront for the exclusive worldwide rights to two undisclosed, preclinical RNA-targeting programs in the notoriously tricky indications of Alzheimer’s and Huntington’s diseases.
Ionis will take the programs through preclinical studies before Roche takes over sole responsibility for human trials and potentially commercialization.
As well as the upfront cash, the Big Pharma agreed to pay development, regulatory and commercial milestones. But the companies are keeping the amount of biobucks at stake under wraps.
“Our lasting partnership with Ionis, a leader in RNA-targeted therapeutics, is a great example of two collaborators mutually benefiting from their relationship by complementing and learning from each other,” James Sabry, Ph.D., global head of Roche Pharma Partnering, said in this morning’s release.
“By expanding our alliance, we bring together the companies’ combined knowledge of the science in Alzheimer’s disease and Huntington’s disease with Roche’s proven capabilities in the development and commercialization of innovative treatments in neuroscience,” Sabry added.
Roche has already been burned attempting to treat both diseases. Its major Alzheimer’s contender, gantenerumab, failed to improve cognitive and functional decline in the two much-anticipated trials from the GRADUATE program in November of last year, leading the Big Pharma to cut most of the program.
However, Roche does have a number of other potential Alzheimer’s therapies in its pipeline, including the AC Immune-partnered anti-amyloid-beta antibody called crenezumab, which has also come up short in the clinic.
Keeping it company in phase 2 are the UCB-partnered anti-tau antibody bepranemab, the AC Immune-partnered anti-tau antibody semorinemab and a different formulation of gantenerumab called trontinemab.
Unlike those antibody therapies, today’s Ionis alliance means Roche could soon add an RNA approach to its Alzheimer’s portfolio.
It’s not the company’s first push into this area, however. In 2021, the Big Pharma signed a pact with Shape Therapeutics to use its RNA-editing platform to explore next-generation gene therapies for Alzheimer’s, Parkinson’s and rare diseases.
When it comes to Huntington’s, Roche and Ionis have previous experience due to their collaboration on tominersen for the past decade. The partners have pressed ahead with a phase 2 trial of the antisense drug in a subgroup of patients despite a late-stage study providing to be one of the highest profile flops of 2021.
“Collaborating on these two programs enables Ionis to advance our wholly owned programs, including those in neurology, aligned with our strategic priorities,” Ionis CEO CEO Brett Monia, Ph.D., added in today’s release.
Check out our mRNA service to expedite your vaccine research
PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha™ 293 cell AAV high-yield platform and the π-Omega™ plasmid high-yield platform. PackGene’s mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.
Another Two-Plasmid AAV Gene Therapy Enters Clinical Trial: Gene Vector Biotechnology’s JWK001 Pioneers in Treating nAMD
On November 30, 2023, Gene Vector Biotechnology Co., Ltd. in Chengdu, China, received approval from the National Medical Products Administration's Center for Drug Evaluation (CDE) for the clinical trial of JWK001, a Class I gene therapy drug for treating neovascular...
Accelerating Gene Therapy Production: Combining next-generation AAV vectors and artificial intelligence (AI)
Recently, the France-based WIDGeT consortium emerged from a collaboration between Sanofi, WhiteLab Genomics, the TaRGeT Laboratory at Nantes University, and Institut Imagine. Scientists and companies in this consortium hope to speed up the development of gene...
First patient received dose level 2 of RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin On track for pivotal dose determination and initiation of pivotal program in 2024...
Hodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0The University of Pennsylvania plans to continue offering CAR-T therapy, a cancer treatment pioneered at Penn, after the Food and Drug...
Plasmids GMP Services
Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
AAV GMP Services
Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.